Home
Resources
Publications
Management of Resistant Trichomoniasis

Management of Resistant Trichomoniasis

Cynthia Alessio, Paul Nyirjesy

Curr Infect Dis Rep. 2019 Aug 6;21(9):31.

PMID: 31388764

Abstract:

Purpose of review:
Trichomonas vaginalis is the most prevalent sexually transmitted parasite in the USA; resistant infection is emerging. New drug therapies and dosing regimens of standard therapies are being studied to treat resistant infection.
Recent findings:
Diagnosis of trichomoniasis has become more sensitive, specific, and widely available with the advent of nucleic acid amplification tests (NAATs). Women with resistant trichomoniasis should be treated with high-dose regimens of metronidazole or tinidazole. Alternative treatment options have been described, and there has been some success particularly with high-dose tinidazole/intravaginal paromomycin cream combination, intravaginal boric acid, and intravaginal metronidazole/miconazole. Resistant trichomoniasis is a growing public health concern with implications for long-term health consequences. More data are needed to further evaluate mechanisms by which resistance occurs as well as promising therapies for those affected.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP19387918-A	Tinidazole		19387-91-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: